Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

8 treatments under study, led by Intravitreal 20 Sulfahexafluoride Sf6 Gas Tamponade

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 3 (1)

Trial Status

Completed1
Recruiting1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04663750Phase 3Recruiting

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

NCT03699618TerminatedPrimary

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

NCT02120066Not ApplicableCompletedPrimary

Submacular Hemorrhage Associated With Retinal Arterial Macro Aneurysm

Showing all 3 trials

Research Network

Common Treatments

  • Intravitreal 20 Sulfahexafluoride Sf6 Gas Tamponade1
  • Pars Plana Vitrectomy1
  • Subretinal Injection Of Recombinant Tpa Alteplase Up To A Maximum Of 25 Micrograms In 02 Mls1
  • Vitrectomy For Submacular Hemorrhage1
  • Antivegf1

Active Sponsors

  • Kyorin University1
  • Johns Hopkins University1
  • King's College Hospital NHS Trust1
  • King's College London1

Top Investigators

Related Conditions

  • Macular Degeneration Wet1
  • Wet Macular Degeneration1
  • Neovascular Agerelated Macular Degeneration1
  • Eye Diseases1
  • Ruptured Retinal Arterial Macro Aneurysms1

Activity Timeline